All Achievements
activity Moderator: "Hodgkin Lymphoma and T/NK Cell Lymphomas, Clinical and Epidemiological: Topics in T Cell, Sezary and Hodgkin Lymphomas"
Abstract/SynopsisAbstract Reviewer/Session Moderator
activity A Real World Experience of Combined Therapy with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma- a Bridge to Transplant and an Effective Salvage for the Unfit
activity Genomic Sequencing of Paired Bone mMaroow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma before and after Induction Therapy
activity Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
activity A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell Lymphoma
activity HDAC inhibitors, updates and combination regimens
activity A Real World Experience of Combined Treatment with Romidepsin and Azacitidine in Patients with Peripheral T-Cell lymphoma
activity Post Transplant Lymphoproliferative Disorders
activity The Integration of PD1 Blockade with Epigenetic Therapy is Highly Active and Safe in Heavily Treated Patients with T-Cell Lymphoma
activity Cell of Origin and Treatment Impact on the Outcome of Monomorphic Post-Transplant Lymphoproliferative Disorder- Diffuse Large B Cell Lymphoma Subtype
activity Targeting the Peripheral T-Cell Lymphoma (PTCL) Epigenome with Oral 5-Azacitidine and Romidepsin: Results and Clinical-Molecular Correlations from a Phase 2 Study
activity Ocular Adnexa Marginal Zone Lymphomas
Abstract/SynopsisOcular adnexa marginal zone lymphoma case presentation and review of the literature
activity Combined Hypomethylating Agents (HMA) and Histone Deacetylase Inhibitors (HDACi) Exhibit Compelling Activity in Patients with Peripheral T-Cell Lymphoma (PTCL) with High Complete Response Rates in Angioimmunoblastic T-Cell Lymphoma (AITL).
activity Prolonged Overall Survival (OS) in a Subset of Responders to the Combination of Brentuximab Vedotin (Bv) and Bendamustine (B) in Heavily Treated Patients with Relapsed or Refractory Hodgkin Lymphoma (HL): Results of an International Multi- Center Phase I/II Experience
activity PTCL NOS: New Treatment Platforms
Abstract/SynopsisPTCL NOS case presentation and overview of new treatment platforms
activity The Impact of Immunophenotypic Subtypes and Treatment Regimens on Patient Outcomes in Monomorphic Post-Transplant Lymphoproliferative Disorders (Diffuse Large B-Cell Lymphoma
activity Hodgkin's Lymphoma Cell Lines Have up-Regulated IL-3 Receptor {alpha} (IL-3R{alpha}) Expression and Are Sensitive to SL-401, An IL-3R{alpha} Targeted Drug
activity Post transplant lymphoproliferative disorders: prognostic features and rituximab impact in a 120 case single institution series
activity T-cell monomorphic post-transplant lymphoproliferative disorders (T-cell m-PTLD): Clinical characteristics and prognostic assessment of a serious complication after transplant
activity Clinical features of bone marrow involvement in marginal zone Lymphomas: analysis of 120 patients